When could retatrutide reach the UK?
Short answer: not before 2028 through a pharmacy, and likely later on the NHS. Here is the full pathway, the dates that are confirmed, and the ones that are educated projection.
Independently written · Last reviewed: · editorial policy
Key facts in 30 seconds
- The one firm date: Lilly plans to file its FDA Biologics License Application in Q1 2027 (stated 23 July 2026).
- Projection: MHRA marketing authorisation around 2028; private UK pharmacy supply from 2028 at the earliest.
- Projection: NICE appraisal from 2029 onwards; NHS availability 2029–2030+, phased to highest clinical need.
- The bottleneck: the TRIUMPH-Outcomes cardiovascular trial is not expected to complete until around 2029.
- There is no legal “early access” — any paid early-access or reservation offer is a scam.
What is confirmed — and what is projection
| Stage | Timing | Status |
|---|---|---|
| FDA Biologics License Application filed by Lilly | Q1 2027 | Stated by Lilly, 23 July 2026 — the one firm date in the whole pathway |
| FDA decision | Late 2027 – 2028 | Projection — standard review takes roughly 10–12 months after acceptance |
| MHRA marketing authorisation | Around 2028 | Projection — MHRA review typically runs about 7–8 months; the UK usually files close behind or in parallel with the US |
| Private UK pharmacy supply | 2028 at the earliest | Projection — follows authorisation plus pricing and supply decisions |
| NICE technology appraisal | 2029 onwards | Projection — NICE weighs cost-effectiveness, including the long-term outcomes data that only arrives around 2029 |
| NHS availability | 2029–2030+ | Projection — and, if tirzepatide is the template, a phased rollout prioritising highest clinical need over years |
How the UK process works, step by step
1. MHRA marketing authorisation
The Medicines and Healthcare products Regulatory Agency decides whether the medicine is safe, effective and well-manufactured enough to be sold in Great Britain. Since Brexit the MHRA runs its own procedure, though it can take part in international work-sharing to speed things up. Retatrutide currently has no entry in the MHRA register — the very first step has not happened.
2. NICE appraisal
For NHS use, the National Institute for Health and Care Excellence must decide the medicine is cost-effective. NICE will want the full trial datasets and, increasingly for weight-management medicines, evidence on long-term cardiovascular outcomes. That is the bottleneck: the dedicated cardiovascular outcomes trial (TRIUMPH-Outcomes) is not expected to complete until around 2029.
3. NHS commissioning and phased rollout
Even after a positive NICE recommendation, NHS supply starts in phases. Tirzepatide — recommended by NICE in late 2024 — is being introduced over years, starting with people at the highest BMI with the most weight-related conditions. There is no reason to expect retatrutide, a likely premium-priced medicine, to be treated more generously. Scotland, Wales and Northern Ireland assess and commission separately (SMC, AWMSG and the Department of Health NI), so dates can diverge across the four nations.
Things that could move the dates
- Faster: MHRA work-sharing with other regulators; a priority review in the US; NICE running its appraisal in parallel with authorisation (as it increasingly does).
- Slower: FDA or MHRA queries on manufacturing (Lilly cited chemistry-and-manufacturing work as a reason the filing moved from 2026 to Q1 2027); safety signals in the remaining trials; pricing disputes.
- Not a real factor: public demand. Regulators do not accelerate because people want a product sooner — and you should treat any website claiming “early UK access” for payment as a scam. There is no legal early access.
The realistic summary for UK readers
- Want retatrutide specifically? The wait is years. Nobody can sell it to you lawfully today.
- Want effective treatment soon? Mounjaro and Wegovy are authorised now, privately through GPhC-registered pharmacies, and on a limited, phased NHS basis. See our comparison page.
- Curious about trials? Legitimate TRIUMPH recruitment runs through official registries — real trials never charge for the medicine.
Cite this page
Johnson N. Yezz — independent UK retatrutide information. Medstack Ltd, 10 September 2026. https://yezz.co.uk/uk-approval-timeline
Sources
Every factual claim on this page traces to one of these primary sources. We link out so you can check the original.
- 1.Retatrutide UK: availability, trial results and legal status — UK-specific pathway projections, updated 31 July 2026
- 2.Retatrutide FDA approval timeline 2026–2028 — BLA plan, review durations and TRIUMPH-Outcomes dates
- 3.Drugs.com — retatrutide approval history — Lilly filing announcement of 23 July 2026
- 4.MHRA products register — current UK authorisation status (none)
- 5.NICE — technology appraisal process for NHS access